Impax Sued by Avanir Over Patent for Nuedexta Nerve Drug
Lawyers for Avanir contend Impax wrongly plans to market a generic version of the drug, for which a patent was awarded in July, before the patent expires in 2023, according to a complaint filed today in federal court in Wilmington, Delaware.
“Impax’s proposed product is especially adapted for a use that infringes the patent,” Avanir contends in court papers, saying there is “no substantial non-infringing use” for the product.
Avanir, based in Aliso Viejo, California, is asking a judge to rule that the patent is infringed, to order Hayward, California-based Impax not to use the technology and to award unspecified damages.
Reached by telephone, Impax spokesman Mark Donohue declined to comment on the lawsuit.
Avanir reported about $32 million in revenue for the year ending on June 30, according to data compiled by Bloomberg. Impax reported about $573 million in the same period.
The case is Avanir v. Impax, U.S. District Court, District of Delaware (Wilmington).
To see the patent, click: 8,227,484.
To contact the reporter on this story: Phil Milford in Wilmington, Delaware, at firstname.lastname@example.org
To contact the editor responsible for this story: Michael Hytha at email@example.com
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.